Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued:  U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242.  Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly …

Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position Read More »